Cargando…
S6K1 and 4E-BP1 Are Independent Regulated and Control Cellular Growth in Bladder Cancer
Aberrant activation and mutation status of proteins in the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) and the mitogen activated protein kinase (MAPK) signaling pathways have been linked to tumorigenesis in various tumors including urothelial carcinoma (UC). However...
Autores principales: | Nawroth, Roman, Stellwagen, Florian, Schulz, Wolfgang A., Stoehr, Robert, Hartmann, Arndt, Krause, Bernd J., Gschwend, Juergen E., Retz, Margitta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3216974/ https://www.ncbi.nlm.nih.gov/pubmed/22110663 http://dx.doi.org/10.1371/journal.pone.0027509 |
Ejemplares similares
-
Both radiographical and pathological lymph node statuses are independent predictors for survival following neoadjuvant chemotherapy and radical cystectomy for cT3/4 or cN+ bladder cancer
por: Wagner, Julia, et al.
Publicado: (2022) -
Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy
por: Sathe, Anuja, et al.
Publicado: (2018) -
Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients
por: Thalgott, Mark, et al.
Publicado: (2015) -
Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patients
por: Heck, Matthias M., et al.
Publicado: (2013) -
Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy
por: Sathe, A, et al.
Publicado: (2014)